Release Details

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sept. 19, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the UBS Global Life Sciences Conference on Tuesday, September 23, 2008. The presentation will provide an overview of the Company and its clinical and research programs and is scheduled to be broadcast live on Tuesday, September 23 at 4:30 p.m. Eastern Time. The session may be accessed through the Company's web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through October 25, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

CONTACT: for Regeneron Pharmaceuticals, Inc.
Investor Relations, 914-345-7640
invest@regeneron.com
or
Laura Lindsay, 914-345-7800
laura.lindsay@regeneron.com
or
Lauren Tortorete, 212-845-5609
ltortorete@biosector2.com

SOURCE: Regeneron Pharmaceuticals, Inc.